Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01490099
Surveillance Study of NovoRapid® for New Drug Re-examination
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1239
- Registration Number
- NCT01490112
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT01489644
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01489111
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01486862
An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2134
- Registration Number
- NCT01487421
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01486914
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Special Survey for Paediatric Subjects
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT01487382
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: human soluble insulin
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01486966
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 598
- Registration Number
- NCT01486940
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Falun, Sweden
© Copyright 2025. All Rights Reserved by MedPath